Cardiovascular safety assessment of Tanimilast in healthy volunteers
CLI-06001AA1-09
Phase 1 other active
Quick answer
Cardiovascular safety assessment of Tanimilast in healthy volunteers for This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers. is a Phase 1 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A
- Indication
- This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.
- Phase
- Phase 1
- Modality
- other
- Status
- active